Pharvaris to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on novel oral bradykinin-B2-receptor antagonists, announced its participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. Live audio webcasts will be available on their website, with replays for 30 days following each event.

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in the following three upcoming investor conferences in September:

Morgan Stanley 19th Annual Global Healthcare Conference
Format: Live Fireside Chat
Date/Time: Friday, September 10, 2021 at 5:00 PM CEST (11:00 a.m. EDT)

H.C. Wainwright 23rd Annual Global Investment Conference
Format: On Demand Presentation
Date/Time: Monday, September 13, 2021 at 1:00 PM CEST (7:00 a.m. EDT)

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Format: Live Presentation
Date/Time: Tuesday, September 21, 2021 at 3:05 PM CEST (9:05 a.m. EDT)

Live audio webcasts of these presentations will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days after each respective date.

About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.

For more information:
Pharvaris
Maryann Cimino
Director of Corporate Relations
+1-617-710-7305
maryann.cimino@pharvaris.com

Investor Contact
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah.mccabe@sternir.com

Media Contact
Maggie Beller
Russo Partners, LLC
+1-646-942-5631
maggie.beller@russopartnersllc.com

FAQ

What investor conferences is Pharvaris participating in September 2021?

Pharvaris will participate in three conferences: Morgan Stanley 19th Annual Global Healthcare Conference on September 10, H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21.

What is the format of the presentations at the Pharvaris investor conferences?

The presentations will include a live fireside chat, on-demand presentation, and a live presentation format at the respective conferences.

Where can I watch the Pharvaris conference presentations?

Live audio webcasts of the presentations will be available on the Investors section of the Pharvaris website, with replays available for 30 days after each event.

What is Pharvaris's focus in the pharmaceutical industry?

Pharvaris focuses on developing and commercializing novel oral bradykinin-B2-receptor antagonists for treating hereditary angioedema and other bradykinin-mediated diseases.

What is the significance of the date September 21 for Pharvaris?

On September 21, 2021, Pharvaris will present live at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.